Joseph Sarris

Professor of Integrative Mental Health

Data updated

Papers

13 publications

Trials

0 clinical trials

Links

Research Footprint

Joseph Sarris appears in 13 tracked papers (2020–2025), most studied alongside Ayahuasca, LSD and Psilocybin, across Depressive Disorders, Substance Use Disorders (SUD) and Anxiety Disorders.

Most-cited paper: Default Mode Network Modulation by Psychedelics: A Systematic Review (219 citations).

Frequent co-authors: Daniel Perkins, Nathalia Galvão-Coelho and Luiz Tófoli.

Publication Landscape

How the 13 papers Blossom tracks for Joseph Sarris line up by year, topic, and journal. These are the psychedelic-relevant papers in Blossom's records as of July 2026, not a complete bibliography.

How has Joseph Sarris's publishing grown?

Sourced

Tracked papers by publication year. Click a year for the running total.

3papers published in 2021

+200% vs 2020

4 published by 2021

Browse papers

Don't read as total output: only the 13 of 13 tracked papers with a recorded publication date are counted, and these are the psychedelic-relevant papers Blossom tracks, not a complete bibliography. The current year is still filling in.

What does Joseph Sarris publish on?

Sourced

Tracked papers per topic. Orange marks the largest research focus.

Don't read shares as adding to 100%: a paper tagged with several topics counts once per topic. These are the psychedelic-relevant papers Blossom tracks, not a complete bibliography.

Where does Joseph Sarris publish?

Sourced

Tracked papers per journal. Orange marks the most-used journal.

Counts the journal recorded on each tracked paper; preprints and papers with no journal on file are not shown. These are the psychedelic-relevant papers Blossom tracks, not a complete bibliography.

Background & Research

Professor Joseph Sarris is an academic clinician specialising in integrative approaches to mental health, with a sustained research focus on psychedelic substances—particularly ayahuasca—and their psychiatric and neurobiological effects. He has led and contributed to multiple large international cross-sectional surveys examining patterns of ayahuasca use, context and setting influences, and adverse effect profiles, and has extended this epidemiological work into translational studies that probe biological mechanisms underlying clinical effects.

His recent work, as reflected in collaborative projects, includes studies linking changes in inflammatory biomarkers to the antidepressant effects of ayahuasca, exploratory clinical pharmacology investigations of oral DMT and harmala alkaloid formulations, and analyses of how naturalistic use relates to current alcohol and other drug use. Across these projects he has emphasised safety, set-and-setting considerations, and rigorous measurement of both subjective outcomes and objective biomarkers, contributing to a nuanced evidence base for the therapeutic potential and risks of ayahuasca and related compounds.

Key Impact

A leading researcher in clinical and epidemiological studies of ayahuasca and related tryptamine formulations, notable for combining large-scale naturalistic surveys with biomarker and translational investigations into therapeutic mechanisms and safety.

13

Research Papers

View publications →

0

Clinical Trials

Explore trials →

Collaboration Network

15 collaborators· click a node to visit their profile

Full network →

Collaboration Network

See Joseph Sarris's full collaboration network, shared papers, and research connections.

Affiliations

Institutions, companies, and organisations Joseph Sarris is associated with.